T-y Kim - Publications

Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer.

Journal: ESMO open

Published: October 14, 2024

Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05.

Journal: ESMO open

Published: May 15, 2024

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 15, 2023

Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 30, 2023

Shear-wave velocity for colorectal cancer liver metastases as a potential prognostic factor after chemotherapy: a preliminary study.

Journal: Clinical radiology

Published: July 25, 2020

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 25, 2019

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 05, 2019

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 01, 2016

Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 25, 2016

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 04, 2015

Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 15, 2015

PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer.

Journal: Oncogene

Published: January 30, 2014